1. Home
  2. ADPT vs CMRE Comparison

ADPT vs CMRE Comparison

Compare ADPT & CMRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$15.14

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo Costamare Inc. $0.0001 par value

CMRE

Costamare Inc. $0.0001 par value

HOLD

Current Price

$15.57

Market Cap

2.0B

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADPT
CMRE
Founded
2009
1974
Country
United States
Monaco
Employees
N/A
1880
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Marine Transportation
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.0B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
ADPT
CMRE
Price
$15.14
$15.57
Analyst Decision
Strong Buy
Hold
Analyst Count
9
1
Target Price
$17.78
$12.00
AVG Volume (30 Days)
1.7M
458.3K
Earning Date
05-05-2026
04-29-2026
Dividend Yield
N/A
3.10%
EPS Growth
63.89
N/A
EPS
N/A
N/A
Revenue
$276,976,000.00
N/A
Revenue This Year
$3.98
N/A
Revenue Next Year
$22.72
N/A
P/E Ratio
N/A
$5.55
Revenue Growth
54.77
N/A
52 Week Low
$9.78
$8.58
52 Week High
$20.76
$18.06

Technical Indicators

Market Signals
Indicator
ADPT
CMRE
Relative Strength Index (RSI) 61.94 38.35
Support Level $14.87 $15.21
Resistance Level $15.27 $17.76
Average True Range (ATR) 0.64 0.54
MACD 0.23 -0.18
Stochastic Oscillator 88.33 23.65

Price Performance

Historical Comparison
ADPT
CMRE

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

About CMRE Costamare Inc. $0.0001 par value

Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and others. The company provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.

Share on Social Networks: